Clinical Features Analysis and Survival Nomogram of Primary Small Intestinal Diffuse Large B-Cell Lymphoma
Open Access
- 5 September 2022
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 14, 2639-2648
Abstract
Purpose: This study aimed to analyze the clinical features and survival of primary small intestinal diffuse large B-cell lymphoma (PsI-DLBCL), and establish and independently validate a prognostic nomogram for individual risk prediction. Patients and methods: Data for 24 patients from the Renmin Hospital of Wuhan University were used as an independent validation cohort, data for 1144 patients with PsI-DLBCL from the SEER database were randomly assigned to training (N=817) and internal validation (N=327) sets. The survival nomogram was constructed with the most significant factors associated with OS using Univariate and multivariate analyses on the training set. Decision curve analysis (DCA) was conducted. Internal validation was SEER validation set. Our cancer center cohort was used as an external validation set to further verify the survival nomogram. Results: Five clinicopathological feature factors associated with OS of the training set yielded (age, marital status, Ann Arbor stage, surgery for primary site and chemotherapy), which were used to create a survival nomogram. Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values. The stability of our survival nomogram was explained by internal and external validation data. Conclusion: Our nomogram proposes the clinical and therapeutic factors affecting OS for patients with PsI-DLBCL. It shows that chemotherapy and surgery are beneficial to patients in the choice of treatment options. These results suggest that a survival nomogram may be better at predicting OS for PsI-DLBCL patients.Keywords
This publication has 25 references indexed in Scilit:
- Primary Gastrointestinal Non-Hodgkin’s Lymphoma of the Small and Large Intestines: a Systematic ReviewJournal of Gastrointestinal Surgery, 2016
- Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sitesBlood Cells, Molecules, and Diseases, 2016
- Primary Gastrointestinal LymphomaMedicine, 2015
- Treatment modalities in primary gastric lymphoma: effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical OncologyContemporary Oncology, 2014
- Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging SystemsJournal of Korean Medical Science, 2014
- Sites of extranodal involvement are prognostic in patients with diffuse large B‐cell lymphoma in the rituximab era: An analysis of the Surveillance, Epidemiology and End Results databaseAmerican Journal of Hematology, 2013
- Bowel perforation in intestinal lymphoma: incidence and clinical featuresAnnals of Oncology, 2013
- Primary gastrointestinal lymphomaWorld Journal of Gastroenterology, 2011
- Efficacy of rituximab in gastric diffuse large B cell lymphoma patientsWorld Journal of Gastroenterology, 2010
- Conservative Management of Gastric Lymphoma: the Treatment Option of ChoiceLeukemia & Lymphoma, 2004